CYP3A4 mutation causes vitamin D–dependent rickets type 3

Genetic forms of vitamin D–dependent rickets (VDDRs) are due to mutations impairing activation of vitamin D or decreasing vitamin D receptor responsiveness. Here we describe two unrelated patients with early-onset rickets, reduced serum levels of the vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and deficient responsiveness to parent and activated forms of vitamin D. Neither patient had a mutation in any genes known to cause VDDR; however, using whole exome sequencing analysis, we identified a recurrent de novo missense mutation, c.902T>C (p.I301T), in CYP3A4 in both subjects that alters the conformation of substrate recognition site 4 (SRS-4). In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency.

[1]  H. Hakonarson,et al.  CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations , 2017, The Journal of clinical endocrinology and metabolism.

[2]  M. Levine,et al.  CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. , 2015, The Journal of clinical endocrinology and metabolism.

[3]  Yanfeng Wang,et al.  Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin , 2014, European Journal of Clinical Pharmacology.

[4]  Dong Li,et al.  Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  C. Peterson,et al.  Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. , 2013, Reproductive toxicology.

[6]  D. Eaton,et al.  Enhancement of hepatic 4‐hydroxylation of 25‐hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: Implications for drug‐induced osteomalacia , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  E. Schuetz,et al.  Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. , 2012, Biochemical pharmacology.

[8]  T. Baillie,et al.  An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway , 2012, Molecular Pharmacology.

[9]  Kenneth E Thummel,et al.  Simultaneous measurement of plasma vitamin D(3) metabolites, including 4β,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[10]  Natasha T. Snider,et al.  Effects of a Commonly Occurring Genetic Polymorphism of Human CYP3A4 (I118V) on the Metabolism of Anandamide , 2010, Drug Metabolism and Disposition.

[11]  A. Halpern,et al.  Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. , 2010, Journal of the American Academy of Dermatology.

[12]  Ravinder J. Singh,et al.  Comparison of Metabolism of Vitamins D2 and D3 in Children With Nutritional Rickets , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  K. Han,et al.  The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density , 2009, Clinical pharmacology and therapeutics.

[14]  L. Bertilsson,et al.  4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians , 2008, Pharmacogenetics and genomics.

[15]  J. Halpert,et al.  CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Adams,et al.  Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Inouye,et al.  Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. , 2000, European journal of biochemistry.

[19]  J. Halpert,et al.  Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. , 2000, Archives of biochemistry and biophysics.

[20]  S. Kato,et al.  Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. , 1998, The New England journal of medicine.

[21]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[22]  R. Ray,et al.  Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. , 1989, The Biochemical journal.

[23]  M. Haussler,et al.  Vitamin D3--resistant fibroblasts have immunoassayable 1,25-dihydroxyvitamin D3 receptors. , 1984, Science.